相关实验视频
Updated: Mar 7, 2026
07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
25.3K
重叠的病理:上腺功能不足呈现为耐火性急性心力衰竭
Ran Sumida1, Yuko Kato2, Naoharu Yagi2
1Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Journal of cardiology cases
|March 6, 2026
概括
孤立上腺皮质激素 (ACTH) 缺乏症是一种罕见的疾病,可以在心力衰竭期间出现. 及时的皮松治疗迅速改善了患有耐火性心力衰竭的患者,强调了考虑上腺功能不充分的重要性.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 孤立的上腺皮质激素 (ACTH) 缺乏是二次上腺功能不充分的罕见原因.
- 身体压力,如心房动或急性心力衰竭,可以揭露ACTH缺乏.
- 上腺功能不全的症状可能会与急性不补偿性心力衰竭 (ADHF) 重叠,使诊断复杂化.
研究的目的:
- 报告一种孤立的ACTH缺乏症病例,该病例是由心动脉动诱导的急性不补偿心力衰竭所揭露的.
- 要突出诊断在区分上腺危机和ADHF的诊断挑战.
- 强调在耐火性心力衰竭中考虑上腺功能不充分的重要性.
主要方法:
- 一个69岁的男性患有心动脉动和ADHF的病例报告.
- 持续性低血和低血压对标准治疗没有反应的评估.
- 内分泌评估显示ACTH和皮质醇水平较低.
- 用皮治疗和监测血液动力学和电解质反应.
主要成果:
- 患者在ADHF期间出现了耐药性低血压和低血压.
- 内分泌检测证实了孤立的ACTH缺乏.
- 皮的使用导致血液动力学和电解质平衡的快速改善.
- 这表明皮质类固醇在管理这种病例中起着至关重要的作用.
结论:
- 上腺功能衰竭应该是患有耐心心力衰竭,持续性低血和低血压的患者的关键差异诊断.
- 经验性皮质类固醇治疗可以挽救生命,并且应该在怀疑上腺危机时立即开始,甚至在荷尔蒙确认之前.
- 早期识别和治疗ACTH缺乏对于患者的治疗结果至关重要.
相关概念视频
01:26Heart Failure III: Clinical Manifestations
743
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
743
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:27Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Heart Failure V: Medical Management
441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441